Chronic infections and atherosclerosis

Journal of the Medical Association of Thailand

Volumn 84, Issue SUPPL. 3, 2001, Pages

  Wattana Leowattana, M D ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Chronic Infection; CMV; Coronary Heart Disease; Helicobactor pylori

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; IMMUNOGLOBULIN G; PLACEBO; ROXITHROMYCIN;

ANTIBODY TITER; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CIGARETTE SMOKING; CLINICAL TRIAL; CYTOMEGALOVIRUS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; HELICOBACTER PYLORI; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; ISCHEMIC HEART DISEASE; NONHUMAN; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION;

BACTERIAL INFECTIONS; CHLAMYDIA INFECTIONS; CHRONIC DISEASE; CORONARY ARTERIOSCLEROSIS; CYTOMEGALOVIRUS INFECTIONS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RISK FACTORS;

EID: 14244271091     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-9.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Leinonen M. Chlamydia pneumoniae and other risk factors for atherosclerosis. J Infect Dis 2000; 181 (Suppl 3): S414-6.
4. Mehta JL, Saldeen TG, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998; 31: 1217-25.
5. Memon RA, Staprans I, Noor M, et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vase Biol 2000; 20: 1536-42.
6. Melnick JL, Adam E, DeBakey ME. Cytomegalovirus and atherosclerosis. Arch Immunol Ther Exp 1996; 44: 297-302.
7. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in Human Carotid Atherosclerotic Plaques. Stroke 2001; 32: 385-91.
8. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J 1993; 14 (Suppl K): 12-6.
9. Benitez RM. Atherosclerosis: An infectious disease? Hosp Pract (Off Ed) 1999; 34: 79-82.
10. Cassell GH. Infectious causes of chronic inflammatory diseases and cancer. Emerg Infect Dis 1998; 4: 475-87.
11. Folsom AR, Nieto FJ, Sorlie P, Chambless LE, Graham DY. Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation 1998; 98: 845-50.
12. Farsak B, Yildirir A, Akyon Y, et al. Detection of Chlamydia pneumoniae and helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 2000; 38: 4408-11.
13. Gasbarrini A, Cremonini F, Armuzzi A, et al. The role of Helicobacter pylori in cardiovascular and cerebrovascular diseases. J Physiol Pharmacol 1999; 50: 735-42.
14. Bertrand ME, Bauters C. Cytomegalovirus infection and coronary restenosis. Circulation 1999; 99: 1278-9.
15. Horvath R, Cerny J, Benedik J, Hokl J, Jelinkova I. The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. J Clin Virol 2000; 16: 17-24.
16. Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: The atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2000; 160: 2027-32.
17. Gupta S, Camm AJ. Chronic infection in the etiology of atherosclerosis - the case for Chlamydia pneumoniae. Clin Cardiol 1997; 20: 829-36.
18. Saikku P. Chlamydia pneumoniae and atherosclerosis - an update. Scand J Infect Dis 1997; 104 (Suppl): 53-6.
19. Numazaki K, Chiba S. Chlamydia pneumoniae infection and coronary heart disease. Role of C pneumoniae in pathogenesis of atherosclerosis must be determined. BMJ 1997; 315: 1538.
20. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350: 430-6.
21. Blum A, Giladi M, Weinberg M, et al. High anticytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998; 81: 866-8.
22. Adam E, Melnick JL, Probtsfield JL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987; 2: 291-3.
23. Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994; 42: 170-4.
24. Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94: 922-7.
25. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-30.
26. Tanaka K, Zou JP, Takeda K, et al. Effects of human cytomegalovirus immediate-early proteins on p53- mediated apoptosis in coronary artery smooth muscle cells. Circulation 1999; 99: 1656-9.
27. Zhou YF, Shou M, Guetta E, et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 1999; 100: 1569-75.
28. Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. Helicobacter pylori infection and early onset myocardial infarction: Case-control and sibling pairs study. BMJ 1999; 319: 1157-62.
29. Cammarota G, Pasceri V, Papa A, et al. Helicobacter pylori infection and ischaemic heart disease. Ital J Gastroenterol Hepatol 1998; 30 (Suppl 3): S304-6.
30. Danesh J. Is there a link between chronic Helicobacter pylori infection and coronary heart disease? Eur J Surg Suppl 1998; 582: 27-31.
31. Saikku P. Chlamydia pneumoniae in atherosclerosis. J Intern Med 2000; 247: 391-6.
32. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/ Atherosclerosis Study Group. Ann Intern Med 1996; 125: 979-82.
33. Kuo C, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis 2000; 181 (Suppl 3): S432-6.
34. Leowattana W, Mahanonda N, Bhuripunyo K, Leelarasamee A, Pokum S, Suwimol B. The prevalence of Chlamydia pneumoniae antibodies in Thai patients with coronary artery disease. J Med Assoc Thai 1999; 82: 792-7.
35. Maass M, Bartels C, Kruger S, Krause E, Engel PM, Dalhoff K. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis 1998; 140 (Suppl 1): S25-30.
36. Miyashita N, Toyota E, Sawayama T, et al. Association of chronic infection of Chlamydia pneumoniae and coronary heart disease in the Japanese. Intern Med 1998; 37: 913-6.
37. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-61.
38. Glader CA, Boman J, Saikku P, et al. The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. Eur Heart J 2000; 21: 639-46.
39. Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis. BMJ 2000; 321: 208-13.
40. Matturri L, Cazzullo A, Turconi P, Roncoroni L, Grana D, Milei J. Inflammatory cells, apoptosis and Chlamydia pneumoniae infection in atherosclerosis. Int J Cardiol 2000; 75: 23-33.
41. Nadrchal R, Makristathis A, Apfalter P, et al. Detection of Chlamydia pneumoniae DNA in atheromatous tissues by polymerase chain reaction. Wien Klin Wochenschr 1999; 111: 153-6.
42. Wong Y, Thomas M, Tsang V, Gallagher PJ, Ward ME. The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. J Am Coll Cardiol 1999; 33: 152-6.
43. Maass M, Bartels C, Engel PM, Marmt U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-32.
44. Kalayoglu MV, Byme GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 1998; 66: 5067-72.
45. Summersgill JT, Molestina RE, Miller RD, Ramirez JA. Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis 2000; 181 (Suppl 3): S479-82.
46. Gaydos CA. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis 2000; 181 (Suppl 3): S473-8.
47. Rodel J, Woytas M, Groh A, et al. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun 2000; 68: 3635-41.
48. Gaydos CA, Quinn TC. The role of Chlamydia pneumoniae in cardiovascular disease. Adv Intern Med 2000;45:139-73.
49. Quinn TC, Gaydos CA. In vitro infection and pathogenesis of Chlamydia pneumoniae in endovascular cells. Am Heart J 1999; 138 (5 Pt 2): S507-11.
50. Naidu BR, Ngeow YF, Kannan P, et al. Evidence of Chlamydia pneumoniae infection obtained by the polymerase chain reaction (PCR) in patients with acute myocardial infarction and coronary heart disease. J Infect 1997; 35: 199-200.
51. Boman J, Gaydos CA. Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells. J Infect Dis 2000; 181 (Suppl 3): S452-4.
52. Maass M, Jahn J, Gieffers J, Dalhoff K, Katus HA, Solbach W. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis 2000; 181 (Suppl 3): S449-51.
53. Mahony JB, Chong S, Coombes BK, Smieja M, Petrich A. Analytical sensitivity, reproducibility of results, and clinical performance of five PCR assays for detecting Chlamydia pneumoniae DNA in peripheral blood mononuclear cells. J Clin Microbiol 2000; 38: 2622-7.
54. Wong YK, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34: 1435-9.
55. Campbell LA, Blessing E, Rosenfeld M, Lin T, Kuo C. Mouse models of C. pneumoniae infection and atherosclerosis. J Infect Dis 2000; 181 (Suppl 3): S508-13.
56. Fong IW. Antibiotics effects in a rabbit model of Chlamydia pneumonias-induced atherosclerosis. J Infect Dis 2000; 181 (Suppl 3): S514-8.
57. Rothstein NM, Quinn TC, Madico G, Gaydos CA, Lowenstein CJ. Effect of Azithromycin on Murine Arteriosclerosis Exacerbated by Chlamydia pneumoniae. J Infect Dis 2001; 183: 232-8.
58. Burnett MS, Gaydos CA, Madico GE, et al. Atherosclerosis in apoE Knockout Mice Infected with Multiple Pathogens. J Infect Dis 2001; 183: 226-31.
59. Muhlestein JB. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J Infect Dis 2000; 181 (Suppl 3): S505-7.
60. Fong IW, Chiu B, Viira E, et al. Can an antibiotic (macrolide) prevent Chlamydia pneumomae-induced atherosclerosis in a rabbit model? Clin Diagn Lab Immunol 1999; 6: 891-4.
61. Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 2000; 102: 1039-44.
62. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo C. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999; 180: 238-41.
63. Campbell LA, Kuo C. Mouse models of Chlamydia pneumoniae infection and atherosclerosis. Am Heart J 1999; 138 (5 Pt 2): S516-8.
64. Kalayoglu MV, Indrawati I, Morrison RP, Morrison SG, Yuan Y, Byrne GI. Chlamydial virulence determinants in atherogenesis: The role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage- lipoprotein interactions. J Infect Dis 2000; 181 (Suppl 3): S483-9.
65. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
66. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350: 404-7.
67. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-7.